GNRH1 and prostate carcinoma: The HERO study by Shore et al. [13] randomly assigned patients with advanced prostate cancer to daily oral relugolix (LHRH antagonist) or long-acting leuprolide (LHRH long-acting agonist) injections once every 3 months.